3 月 2 日,康方生物宣布,在第 27 届欧洲妇科肿瘤学大会(ESGO 2026)上,研究人员公布了卡度尼利(PD-1/CTLA-4 双抗)单药治疗既往接受含铂化疗治疗失败的复发/转移性宫颈癌的关键注册性 II 期研究(COMPASSION-03/AK104-201)最新长期生存分析数据。最佳总体缓解(BOR)分析展现卓越生存获益本次在ESGO大会上公布的更新数据中位随访时间为26.5个月,研究...
Source Link3 月 2 日,康方生物宣布,在第 27 届欧洲妇科肿瘤学大会(ESGO 2026)上,研究人员公布了卡度尼利(PD-1/CTLA-4 双抗)单药治疗既往接受含铂化疗治疗失败的复发/转移性宫颈癌的关键注册性 II 期研究(COMPASSION-03/AK104-201)最新长期生存分析数据。最佳总体缓解(BOR)分析展现卓越生存获益本次在ESGO大会上公布的更新数据中位随访时间为26.5个月,研究...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.